Value of SERMs in postmenopausal women

Lancet. 2004 May 1;363(9419):1477-8. doi: 10.1016/S0140-6736(04)16118-7.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Bone Density
  • Cardiovascular Diseases / prevention & control
  • Estrogen Replacement Therapy / adverse effects
  • Female
  • Humans
  • Postmenopause*
  • Raloxifene Hydrochloride / therapeutic use
  • Selective Estrogen Receptor Modulators / chemistry
  • Selective Estrogen Receptor Modulators / therapeutic use*

Substances

  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride